- Home
- INMB vs EVAX Comparison
INMB vs EVAX Comparison
Compare INMB & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | EVAX |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 33.4M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INMB | EVAX |
|---|---|---|
| Price | $1.44 | $3.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.30 | ★ $12.33 |
| AVG Volume (30 Days) | ★ 332.6K | 77.3K |
| Earning Date | 03-26-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $50,000.00 | ★ $7,650,000.00 |
| Revenue This Year | $264.29 | $128.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 19.05 | ★ 132.17 |
| 52 Week Low | $1.38 | $1.20 |
| 52 Week High | $11.64 | $12.15 |
Technical Indicators
Market Signals| Indicator | INMB | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 37.50 |
| Support Level | $1.44 | $3.06 |
| Resistance Level | $1.67 | $3.66 |
| Average True Range (ATR) | 0.12 | 0.33 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 12.82 | 33.26 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.